Details of the Drug Reposition

General Information of This Drug (ID: DMB5N7B)

Drug Name
Modakafusp alfa   DMB5N7B
Synonyms TAK-573

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Aggressive cancer DISKUCQY 2A00-2F9Z Phase 1/2 [1]
Multiple myeloma DISEWP9B 2A83 Phase 1/2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04157517) An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05590377) A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health.